Becton, Dickinson and Company (BDX) Holdings Cut by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 868,060 shares of the medical instruments supplier’s stock after selling 119,170 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.41% of Becton, Dickinson and worth $169,368,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in Becton, Dickinson and by 1.4% during the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after acquiring an additional 13,263 shares in the last quarter. Boston Financial Mangement LLC raised its stake in Becton, Dickinson and by 10.2% during the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after acquiring an additional 5,152 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Becton, Dickinson and by 5.8% during the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after acquiring an additional 1,819 shares in the last quarter. Wells Fargo & Company MN raised its stake in Becton, Dickinson and by 1.2% during the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after acquiring an additional 39,362 shares in the last quarter. Finally, AMG National Trust Bank raised its stake in Becton, Dickinson and by 4.2% during the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock worth $1,813,000 after acquiring an additional 401 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

Several research firms have issued reports on BDX. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. Cowen and Company reiterated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has a consensus rating of “Buy” and an average target price of $195.79.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 203.70 on Monday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market capitalization of $46.35 billion, a price-to-earnings ratio of 58.99 and a beta of 1.06. The stock has a 50 day moving average price of $200.12 and a 200-day moving average price of $190.74.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the previous year, the firm earned $2.35 EPS. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.43%. Becton, Dickinson and’s payout ratio is presently 83.43%.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,605 shares of company stock valued at $9,718,986. Insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/11/becton-dickinson-and-company-bdx-holdings-cut-by-schwab-charles-investment-management-inc.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply